Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme.

Abstract:

OBJECTIVE:This two-arm longitudinal study was performed within a regional organized cervical-cancer-prevention program in which HPV-DNA test is used in primary screening. The aim was to analyze the diagnostic performances of p16INK4a/Ki-67 dual-test and E6/E7-mRNA test in identifying CIN2+ lesion among HPV-DNA positive (HPV-DNAve) women triaged for LSIL-or-worse liquid based cytology (LBC). METHODS:Thirty-six thousand thirty-one women participated to HPV-DNA screening program pilot study. Three thousand six hundred forty-one resulted HPV-DNAve; among these, 43% were LSIL-or-worse (LSIL+). HPV-DNAve/LSIL+ patients were submitted to colposcopy and histological assessment of any visible lesions. Dual-test was performed on 794 residual LBC specimens. In 405 cases, dual-test result was related to histology, considering CIN2+ as endpoint. mRNA test has been carried out retrospectively, on a subset of 173 residual LBC specimens. RESULTS:Agreement between dual-test and histological diagnosis was 59%. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of cytology-plus-dual-test approach were 62.3%, 76.8%, 63.1% and 84.2%, respectively. Dual-test improved specificity, PPV and NPV of cytological triage Agreement between mRNA testing and histology was 65%. Cytology-plus mRNA testing showing sensitivity, specificity, PPV and NPV reaching 32.1%, 94.9%, 75% and 50%, respectively; implemented specificity and PPV of cytology alone in triaging DNA-ve/LSIL+ patients (p<0.01). CONCLUSIONS:We provided promising data indicating the important role that p16(INK4)/Ki-67 dual-test, and mostly E6/E7 mRNA test, might have in triaging HPV-DNAve. These approaches would exclude the occurrence of cervical cancer and would avoid overtreatment, at the same time. Further longitudinal analysis has to be considered.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Zappacosta R,Caraceni D,Ciccocioppo L,Rotondo T,Capanna S,Gatta DM,D'Angelo C,Rosini S

doi

10.1016/j.ygyno.2012.11.030

subject

Has Abstract

pub_date

2013-03-01 00:00:00

pages

427-32

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(12)00896-7

journal_volume

128

pub_type

杂志文章
  • Patient characteristics and opioid use prior to discharge after open gynecologic surgery in an enhanced recovery after surgery (ERAS) program.

    abstract:OBJECTIVE:To identify clinical and demographic characteristics associated with the absence of opioid usage on the day before discharge among patients undergoing open gynecologic surgery within an enhanced recovery after surgery (ERAS) program. METHODS:This was a single institution retrospective cohort study including ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.03.101

    authors: Hillman RT,Sanchez-Migallon A,Meyer LA,Iniesta MD,Cain KE,Siverand AM,Veum SPL,Suki TS,Lasala JD,Ramirez PT

    更新日期:2019-06-01 00:00:00

  • Use of CA 125 to monitor patients with ovarian epithelial carcinomas.

    abstract::The CA 125 radioimmunoassay has been increasingly used to monitor the course of patients with ovarian epithelial carcinomas. The purpose of this report is to describe our experience in the use of this assay and to better define its clinical utility. Fifty-one patients had serum CA 125 follow-up during primary chemothe...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90550-7

    authors: Podczaski E,Whitney C,Manetta A,Larson JE,Kirk J,Stevens CW,Lyter J,Mortel R

    更新日期:1989-05-01 00:00:00

  • Syndrome of inappropriate antidiuresis in ovarian serous carcinoma with neuroendocrine differentiation.

    abstract::A 58-year-old postmenopausal woman with primary ovarian serous carcinoma presented with the syndrome of inappropriate antidiuresis (SIAD). Preoperative workup showed serum sodium level of 110 mEq/liter and antidiuretic hormone level of 3.3 pg/ml. The serum and urine osmolarity were 239 and 371, respectively. Antidiure...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1996.0256

    authors: Taskin M,Barker B,Calanog A,Jormark S

    更新日期:1996-09-01 00:00:00

  • Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.

    abstract:OBJECTIVE:Describe clinical characteristics and risk reducing strategies utilized among women with a BRCA mutation who lived to age 75 and above. METHODS:A retrospective study of women with BRCA mutations identified from 1995 to 2015 in a California health care system. From a database of 1189 women, 69 participants we...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.05.017

    authors: Salyer C,Kobelka C,Barrie A,Weintraub MR,Powell CB

    更新日期:2019-08-01 00:00:00

  • The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors.

    abstract::Tumor specimens from 92 patients with ovarian carcinoma were analyzed for estrogen receptor (ER), progesterone receptor (PR), proliferative fraction, and ploidy. Seventy-one percent of tumors were either ER+ (greater than 5 fmole/mg protein) or PR+ (greater than 10 fmole/mg protein) with 27% of tumors overall being bo...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(89)80031-9

    authors: Friedlander ML,Quinn MA,Fortune D,Foo MS,Toppila M,Hudson CN,Russell P

    更新日期:1989-02-01 00:00:00

  • Is OVX1 a suitable marker for endometrial cancer?

    abstract::The single most common cause leading to the diagnosis of endometrial cancer is postmenopausal bleeding. Although most patients with early-stage disease (FIGO stage I and II) can be cured, prognosis worsens considerably with increasing stage. While serum CA 125 levels are elevated only in a significant proportion of pa...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1997.4620

    authors: Beck EP,Wagner M,Anselmino L,Xu F,Bast RC Jr,Jaeger W

    更新日期:1997-05-01 00:00:00

  • Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.

    abstract:BACKGROUND:Glucocorticoid receptor (GR) has emerged as an important steroid nuclear receptor in hormone dependent cancers, however few data are available regarding a potential role of GR in endometrial cancer. The aim of this study was to investigate expression of GR in primary and metastatic endometrial cancer lesions...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.09.013

    authors: Tangen IL,Veneris JT,Halle MK,Werner HM,Trovik J,Akslen LA,Salvesen HB,Conzen SD,Fleming GF,Krakstad C

    更新日期:2017-12-01 00:00:00

  • Histologic and immunologic associations of an HPV16 variant in LoSIL smears.

    abstract:BACKGROUND:Human papillomavirus type 16 variants have been described and may have different biologic activities: this has implications for the design of HPV vaccines. OBJECTIVES:The aim of this study was to see if the HPV16 variant E-G 131 can be detected in women with preinvasive disease and to consider the histologi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5231

    authors: Etherington IJ,Ellis JR,Luesley DM,Moffitt DD,Young LS

    更新日期:1999-01-01 00:00:00

  • Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas.

    abstract::A retrospective evaluation of 87 cases of uterine sarcoma treated during 1965-1980 at two Swedish hospitals has been made. Adjuvant postoperative radiotherapy has been compared with adjuvant chemotherapy. Various types of combination treatments were also evaluated. Both types of adjuvant therapy seem to reduce the fai...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(85)90209-4

    authors: Sorbe B

    更新日期:1985-03-01 00:00:00

  • Impact of p53 immunostaining in predicting advanced or recurrent placental site trophoblastic tumors: a study of 12 cases.

    abstract:OBJECTIVES:To identify an indicator that can predict tumor cell spread beyond the uterine corpus. METHODS:We studied clinicopathology and immunohistochemistry of 12 cases of PSTT. Two cases of epithelioid trophoblastic tumor (ETT) were included as reference cases. For immunohistochemistry, antibodies against Ki-67, p5...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.04.025

    authors: Nagai Y,Kamoi S,Matsuoka T,Hata A,Jobo T,Ogasawara T,Aoki Y,Ohira S,Okamoto T,Nakamoto T,Kanda K,Matsui H

    更新日期:2007-09-01 00:00:00

  • Evaluation of a one-parameter flow analysis of cervical samples for gynecology cancer screening.

    abstract::A total of 246 endocervical samples were collected for Papanicolaou staining and one-parameter flow cytometric DNA analysis (FCDA) using 4',6-diamidino-2-phenylindole as a DNA stain. Typical histograms derived from FCDA analysis were designated class I, II, III, and V. Two groups of patients were studied: 135 women re...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(83)90049-5

    authors: Tsou KC,Pearson S,Atkinson BF,Giuntoli R,Mangan C

    更新日期:1983-06-01 00:00:00

  • Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.

    abstract:OBJECTIVE:Although the incidence of cervical adenocarcinoma is increasing, few genetic and epigenetic changes in its progression have been described. We hypothesized that RASSF1A methylation and KRAS and BRAF mutations may play an important role in cervical adenocarcinoma. METHODS:Archival primary carcinoma tissues (n...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.01.045

    authors: Kang S,Kim HS,Seo SS,Park SY,Sidransky D,Dong SM

    更新日期:2007-06-01 00:00:00

  • Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007.

    abstract::Advances in surgery and chemotherapy have improved the 5-year survival for patients with epithelial ovarian cancer, but have not impacted on the ultimate rate of cure in a disease that is diagnosed in late stage and that recurs in the majority of patients. "Omic" technologies promise to define genetically driven aberr...

    journal_title:Gynecologic oncology

    pub_type: 共识发展会议,杂志文章

    doi:10.1016/j.ygyno.2007.11.014

    authors: Ashworth A,Balkwill F,Bast RC,Berek JS,Kaye A,Boyd JA,Mills G,Weinstein JN,Woolley K,Workman P

    更新日期:2008-03-01 00:00:00

  • PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.

    abstract:OBJECTIVES:To characterize the safety, tolerability, and anti-tumor activity of cemiplimab as monotherapy or in combination with hypofractionated radiation therapy (hfRT) in patients with recurrent or metastatic cervical cancer. To determine the association between histology and programmed death-ligand 1 (PD-L1) expres...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.08.026

    authors: Rischin D,Gil-Martin M,González-Martin A,Braña I,Hou JY,Cho D,Falchook GS,Formenti S,Jabbour S,Moore K,Naing A,Papadopoulos KP,Baranda J,Fury W,Feng M,Stankevich E,Li J,Yama-Dang NA,Yoo SY,Lowy I,Mathias M,Fury

    更新日期:2020-11-01 00:00:00

  • When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic.

    abstract::The COVID-19 pandemic has challenged our ability to provide timely surgical care for our patients. In response, the U.S. Surgeon General, the American College of Srugeons, and other surgical professional societies recommended postponing elective surgical procedures and proceeding cautiously with cancer procedures that...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2020.06.001

    authors: Fader AN,Huh WK,Kesterson J,Pothuri B,Wethington S,Wright JD,Bakkum-Gamez JN,Soliman PT,Sinno AK,Leitao M,Martino MA,Karam A,Rossi E,Brown J,Blank S,Burke W,Goff B,Yamada SD,Uppal S,Dowdy SC

    更新日期:2020-08-01 00:00:00

  • Low-grade ovarian cancer in an adolescent patient.

    abstract:BACKGROUND:Ovarian tumors in the pediatric population are most likely to be of germ cell origin. However, serous tumors have also been reported in adolescent patients. CASE:A 14-year-old girl was diagnosed with stage IIIc low-grade ovarian cancer. Her serum CA-125 was elevated preoperatively and was a marker for recur...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.6020

    authors: Parker LP,Ramirez PT,Broaddus R,Sightler S,Wolf JK

    更新日期:2001-01-01 00:00:00

  • Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer.

    abstract:OBJECTIVES:To construct a tool, using computed tomography (CT) imaging and preoperative clinical variables, to estimate successful primary cytoreduction for advanced epithelial ovarian cancer (EOC). METHODS:Women who underwent primary cytoreductive surgery for stage IIIC/IV EOC at Mayo Clinic between 1/2/2003 and 12/3...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2015.04.013

    authors: Janco JM,Glaser G,Kim B,McGree ME,Weaver AL,Cliby WA,Dowdy SC,Bakkum-Gamez JN

    更新日期:2015-07-01 00:00:00

  • Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

    abstract:PURPOSE:To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PPC) who receive carboplatin and paclitaxel. ME...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.ygyno.2018.07.021

    authors: Olawaiye AB,Java JJ,Krivak TC,Friedlander M,Mutch DG,Glaser G,Geller M,O'Malley DM,Wenham RM,Lee RB,Bodurka DC,Herzog TJ,Bookman MA

    更新日期:2018-10-01 00:00:00

  • Transitional cell carcinoma of the endometrium.

    abstract::Only one case of endometrial transitional cell carcinoma (TCC) has been previously reported in the literature. We report a second case. In both the previously reported case and in this case there was a separate focus of TCC in the adnexa. Both patients were treated with adjuvant whole pelvic radiation and are alive an...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1996.0047

    authors: Spiegel GW,Austin RM,Gelven PL

    更新日期:1996-02-01 00:00:00

  • Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives.

    abstract::Endometrial carcinoma is the most common gynecologic malignancy and the fourth most prevalent cancer in women in the modern world. Despite a relatively high chance of surgical cure, for patients with advanced or recurrent disease there are few therapeutic options. Angiogenesis has been extensively studied ever since v...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2020.12.016

    authors: Berger AA,Dao F,Levine DA

    更新日期:2020-12-26 00:00:00

  • Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database.

    abstract:OBJECTIVE:The aim of the study was to examine whether comorbidity is an independent prognostic factor for 3129 women diagnosed with ovarian cancer from 2005 to 2011. As Performance status (PS) might capture the impact of comorbidity we addressed whether comorbidity can be explained by PS or whether comorbidity has an i...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.12.039

    authors: Sperling C,Noer MC,Christensen IJ,Nielsen ML,Lidegaard Ø,Høgdall C

    更新日期:2013-04-01 00:00:00

  • Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?

    abstract:BACKGROUND:Population-based studies of women with epithelial ovarian cancer suggest that black women have worse survival compared to white women. The primary objective of this study was to determine if, at a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center (CCC) serving a diverse racial and socioe...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.10.035

    authors: Dilley S,Erickson BK,Phillips CE,Kennemer CR,Zhang B,Matin T,Martin JY,Shah MM,Michael Straughn J Jr,Leath CA 3rd

    更新日期:2018-04-01 00:00:00

  • Clear cell carcinoma of the ovary: a review of the literature.

    abstract:OBJECTIVE:Different histologic types of epithelial ovarian cancer may represent different diseases with unique clinical and molecular characteristics. Clear cell carcinoma (CCC) of the ovary has been reported as having a worse prognosis than high grade serous epithelial ovarian cancer (EOC). This article critically rev...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2012.04.021

    authors: del Carmen MG,Birrer M,Schorge JO

    更新日期:2012-09-01 00:00:00

  • Screening as a prognostic factor in cervical cancer: analysis of survival and prognostic factors based on Icelandic population data, 1964-1988.

    abstract::Survival rates were computed for 376 women diagnosed with carcinoma of the uterine cervix between 1964 and 1988. The 5-year survival rate for the entire group was 63%. The effect of age at diagnosis, clinical stage, histopathology, year of diagnosis, and screening program attendance was studied by univariate analysis ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(91)90011-s

    authors: Sigurdsson K,Hrafnkelsson J,Geirsson G,Gudmundsson J,Salvarsdóttir A

    更新日期:1991-10-01 00:00:00

  • Conservative surgery for borderline ovarian tumors: a review.

    abstract:OBJECTIVE:Borderline tumor of the ovary is an epithelial tumor with a low rate of growth and a low potential to invade or metastasize. This review will outline the most recent information regarding the molecular pathogenesis, pathology, fertility and tumor recurrence rate after conservative management of young women wi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2005.09.021

    authors: Tinelli R,Tinelli A,Tinelli FG,Cicinelli E,Malvasi A

    更新日期:2006-01-01 00:00:00

  • Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.

    abstract:OBJECTIVES:We aimed to define the site-specific patterns of treatment failure in stage IV ovarian cancer. METHODS:Data from all consecutive Mayo Clinic patients with stage IV epithelial ovarian cancer, from 1994 through 2003, were collected and analyzed. Statistical analyses included the chi(2) test and Kaplan-Meier c...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.09.010

    authors: Aletti GD,Podratz KC,Cliby WA,Gostout BS

    更新日期:2009-01-01 00:00:00

  • Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?

    abstract::As gynecologic surgeons garnered a better understanding of various clinical-pathological prognostic factors, there evolved a number of modifications in the surgical approach allowing for more individualized therapy with less morbidity, while still retaining the curative potential of the radical vulvectomy operation. T...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2009.01.004

    authors: Moore DH

    更新日期:2009-06-01 00:00:00

  • Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid.

    abstract:OBJECTIVE:Binding of Fas ligand or agonistic anti-Fas antibody to the death receptor Fas can activate a caspase-cascade resulting in apoptosis. In the present study, the functionality of the Fas pathway was studied in human cervical cancer cells with different HPV and p53 status. METHODS:HeLa (HPV-18 positive), CaSki,...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.01.036

    authors: Hougardy BM,van der Zee AG,van den Heuvel FA,Timmer T,de Vries EG,de Jong S

    更新日期:2005-05-01 00:00:00

  • Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis.

    abstract::Between October 1985 and January 1989, 33 patients with stage I (31) or clinically occult stage II (2) endometrial cancer at a high risk for recurrence were entered in a prospective study evaluating adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy. Eligibility criteria included grade 2 tumors w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90063-q

    authors: Stringer CA,Gershenson DM,Burke TW,Edwards CL,Gordon AN,Wharton JT

    更新日期:1990-09-01 00:00:00

  • The NCI-MATCH trial and precision medicine in gynecologic cancers.

    abstract::The Precision Medicine Initiative is a National Cancer Institute (NCI) driven interdisciplinary collaborative effort to test the feasibility of trials incorporating genomic profiling when choosing patient therapies. The goal of the initiative is to generate the scientific evidence needed to move the concept of precisi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2018.01.008

    authors: Barroilhet L,Matulonis U

    更新日期:2018-03-01 00:00:00